We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 22 of 234 for:    "Polycythemia vera"

Natural Killer Cells and Polycythemia Vera (Vaquez's Disease)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01284712
Recruitment Status : Unknown
Verified September 2015 by Assistance Publique Hopitaux De Marseille.
Recruitment status was:  Active, not recruiting
First Posted : January 27, 2011
Last Update Posted : October 1, 2015
Information provided by (Responsible Party):
Assistance Publique Hopitaux De Marseille

Brief Summary:
Natural Killer cells (NK) are pivotal cells of innate immunity, that sense defective expression of HLA class I molecules and are complementary to specific cytotoxic T lymphocytes. A defect in NK cell cytotoxicity has been described in some hematopoietic malignancies such as acute myeloid leukemia, multiple myeloma, myelodysplastic syndroms. This defect is at least partially linked to a decreased or absent expression of some activating NK cell molecules, more particularly the so-called Natural Cytotoxicity Receptors (NCRs) NKp30, NKp44 and NKp46. Some old publications have demonstrated defective NK cytotoxicity in myeloproliferative syndroms (chronic myeloid leukemia, primary thrombocytosis, polycythemia vera). The investigators more particularly focused their attention on polycythemia vera (Vaquez's disease), a myeloproliferative disease characterized by the recently describet mutation V617F of the JAK2 tyrosine kinase. The investigators will precise the mechanisms leading to this cytotoxicity defect, the investigators also will evaluate the implication of V617F mutation on NK physiology, and will study the interactions between NK cells and hematopoietic progenitors.

Condition or disease Intervention/treatment
Polycythemia Vera Biological: blood sample

Study Type : Observational
Estimated Enrollment : 27 participants
Time Perspective: Prospective
Study Start Date : July 2009
Primary Completion Date : July 2013

Intervention Details:
    Biological: blood sample
    blood sample coming from therapeutic bleeding in hospital

Primary Outcome Measures :
  1. To describe immunologic anomalies in polycythemia vera [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Inclusion Criteria:

  • Polycythemia vera
  • Treatment by therapeutic bleedings
  • No cytotoxic treatment during the previous six months

Exclusion Criteria:

  • No Polycythemia vera
  • No treatment by therapeutic bleedings
  • Cytotoxic treatment during the previous six months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01284712

Assistance Publique - Hopitaux de Marseille
Marseille, France
Sponsors and Collaborators
Assistance Publique Hopitaux De Marseille
Principal Investigator: Regis Costello Assistance Publique Hopitaux De Marseille

Responsible Party: Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier: NCT01284712     History of Changes
Other Study ID Numbers: 2009/16
First Posted: January 27, 2011    Key Record Dates
Last Update Posted: October 1, 2015
Last Verified: September 2015

Keywords provided by Assistance Publique Hopitaux De Marseille:
treatment by bleedings

Additional relevant MeSH terms:
Polycythemia Vera
Hematologic Diseases
Bone Marrow Neoplasms
Hematologic Neoplasms
Neoplasms by Site
Bone Marrow Diseases
Myeloproliferative Disorders